Linker Information
General Information of This Linker
| Linker ID |
LIN0TYKTE
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Adcentrx' proprietary linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
ADRX-0706 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible subjects for Phase 1a (dose escalation) must have select advanced solid tumors (e.g., UC, HNSCC, NSCLC) progressing after ≥1 prior therapy, while Phase 1b (dose expansion) focuses on UC, TNBC, or cervical cancer. Exclusions include uncontrolled CNS metastases, significant cardiovascular disease, recent anticancer therapy (<14 days/5 half-lives), and concurrent CYP3A/P-gp modifiers.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06036121 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study will evaluate the incidence of adverse events over an estimated 3-year period, assessing safety throughout the trial duration.
|
||||
| Other Endpoint |
Pharmacokinetic parameters (Cmax, Ctrough, AUC, t1/2, CL, Vss) of ADRX-0706 and immunogenicity via anti-drug antibodies (ADA) will be measured serially over 3 years. Efficacy endpoints include ORR, DOR, DCR, PFS, and OS, all assessed per RECIST 1.1 criteria.
|
||||